FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate - Biomea Fusion ( NASDAQ:BMEA )

3 weeks ago

Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.'s BMEA ongoing Phase 1/2 clinical trials of the company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes ( COVALENT-111 and COVALENT-112 ) , respectively.

Ticker	Sentiment	Impact
BMEA	Somewhat Bullish	39 %